Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(5):760–768. doi: 10.1038/sj.bjc.6690761

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

D R Newell 1, S S Burtles 2, B W Fox 3, D I Jodrell 4, T A Connors 5
PMCID: PMC2374299  PMID: 10555743

Abstract

Preclinical toxicology studies are performed prior to phase I trials with novel cancer therapeutics to identify a safe clinical starting dose and potential human toxicities. The primary aim of this study was to evaluate the ability of rodent-only toxicology studies to identify a safe phase I trial starting dose. In addition, the ability of murine studies to predict the quantitative and qualitative human toxicology of cancer therapeutics was studied. Data for 25 cancer drugs were collated for which the preclinical and clinical routes and schedules of administration were either the same (22/25), or closely matched. The maximum tolerated dose/dose lethal to 10% of mice (MTD/LD10) was identified for 24 drugs, and in patients the maximum administered dose (MAD) was associated with dose-limiting toxicity (DLT) in initial clinical trials with 20 compounds. In addition, for 13 agents, the toxicity of the drug at one-tenth the mouse MTD/LD10 was also investigated in rats, following repeated administration (20 doses). A phase I trial starting dose of one-tenth the mouse MTD/LD10 (mg m–2) was, or would have been, safe for all 25 compounds. With the exception of nausea and vomiting, which cannot be assessed in rodents, other common DLTs were accurately predicted by the murine studies (i.e. 7/7 haematological and 3/3 neurological DLTs). For two of the 13 drugs studied in rats, repeated administration of one-tenth the mouse MTD/LD10 was toxic, leading to a reduction in the phase I trial starting dose; however, one-tenth the mouse MTD/LD10 was subsequently tolerated in patients. For the 20 drugs where clinical DLT was reached, the median ratio of the human MAD to the mouse MTD/LD10 was 2.6 (range 0.2–16) and the median ratio of the clinical starting dose to the MAD was 35 (range 2.3–160). In contrast, in 13 subsequent phase I trials with 11 of the initial 25 drugs, the median ratio of the clinical starting dose to the MAD was 2.8 (range 1.6–56), emphasizing the value of early clinical data in rapidly defining the dose range for therapeutic studies. For all 25 drugs studied, rodent-only toxicology provided a safe and rapid means of identifying the phase I trial starting dose and predicting commonly encountered DLTs. This study has shown that the routine use of a non-rodent species in preclinical toxicology studies prior to initial clinical trials with cancer therapeutics is not necessary. © 1999 Cancer Research Campaign

Keywords: phase I trials, preclinical toxicology, starting dose

Full Text

The Full Text of this article is available as a PDF (94.4 KB).

Footnotes

For the Cancer Research Campaign Phase I/II Clinical Trials Committee

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arbuck S. G. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol. 1996 Aug;7(6):567–573. doi: 10.1093/oxfordjournals.annonc.a010672. [DOI] [PubMed] [Google Scholar]
  2. Betteridge R. F., Bosanquet A. G., Gilby E. D. Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZG, NSC 224070) during a phase I clinical trial. Eur J Cancer. 1990 Feb;26(2):107–112. doi: 10.1016/0277-5379(90)90291-z. [DOI] [PubMed] [Google Scholar]
  3. Burtles S. S., Newell D. R., Henrar R. E., Connors T. A. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office. Eur J Cancer. 1995;31A(3):408–410. doi: 10.1016/0959-8049(94)00483-l. [DOI] [PubMed] [Google Scholar]
  4. Carmichael J., Cantwell B. M., Mannix K. A., Veale D., Elford H. L., Blackie R., Kerr D. J., Kaye S. B., Harris A. L. A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer. 1990 Mar;61(3):447–450. doi: 10.1038/bjc.1990.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Collins J. M., Grieshaber C. K., Chabner B. A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst. 1990 Aug 15;82(16):1321–1326. doi: 10.1093/jnci/82.16.1321. [DOI] [PubMed] [Google Scholar]
  6. Collins J. M., Zaharko D. S., Dedrick R. L., Chabner B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986 Jan;70(1):73–80. [PubMed] [Google Scholar]
  7. DeGeorge J. J., Ahn C. H., Andrews P. A., Brower M. E., Giorgio D. W., Goheer M. A., Lee-Ham D. Y., McGuinn W. D., Schmidt W., Sun C. J. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol. 1998;41(3):173–185. doi: 10.1007/s002800050726. [DOI] [PubMed] [Google Scholar]
  8. Decoster G., Stein G., Holdener E. E. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1(3):175–181. doi: 10.1093/oxfordjournals.annonc.a057716. [DOI] [PubMed] [Google Scholar]
  9. Dent S. F., Eisenhauer E. A. Phase I trial design: are new methodologies being put into practice? Ann Oncol. 1996 Aug;7(6):561–566. doi: 10.1093/oxfordjournals.annonc.a010671. [DOI] [PubMed] [Google Scholar]
  10. Estey E., Hoth D., Simon R., Marsoni S., Leyland-Jones B., Wittes R. Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep. 1986 Sep;70(9):1105–1115. [PubMed] [Google Scholar]
  11. Foster B. J., Newell D. R., Carmichael J., Harris A. L., Gumbrell L. A., Jones M., Goodard P. M., Calvert A. H. Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer. 1993 Feb;67(2):362–368. doi: 10.1038/bjc.1993.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Foster B. J., Newell D. R., Graham M. A., Gumbrell L. A., Jenns K. E., Kaye S. B., Calvert A. H. Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation. Eur J Cancer. 1992;28(2-3):463–469. doi: 10.1016/s0959-8049(05)80077-2. [DOI] [PubMed] [Google Scholar]
  13. Foster B. J., Newell D. R., Gumbrell L. A., Jenns K. E., Calvert A. H. Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer. 1993 Feb;67(2):369–373. doi: 10.1038/bjc.1993.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Freireich E. J., Gehan E. A., Rall D. P., Schmidt L. H., Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966 May;50(4):219–244. [PubMed] [Google Scholar]
  15. Goldsmith M. A., Slavik M., Carter S. K. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 1975 May;35(5):1354–1364. [PubMed] [Google Scholar]
  16. Grieshaber C. K., Marsoni S. Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep. 1986 Jan;70(1):65–72. [PubMed] [Google Scholar]
  17. Homan E. R. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. Cancer Chemother Rep 3. 1972 May;3(1):13–19. [PubMed] [Google Scholar]
  18. Horwich A., Holliday S. B., Deacon J. M., Peckham M. J. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069. Br J Radiol. 1986 Dec;59(708):1238–1240. doi: 10.1259/0007-1285-59-708-1238. [DOI] [PubMed] [Google Scholar]
  19. Jayson G. C., Crowther D., Prendiville J., McGown A. T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer. 1995 Aug;72(2):461–468. doi: 10.1038/bjc.1995.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jodrell D. I., Bowman A., Stewart M., Dunlop N., French R., MacLellan A., Cummings J., Smyth J. F. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously. Br J Cancer. 1998 Mar;77(5):808–811. doi: 10.1038/bjc.1998.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Judson I. R., Calvert A. H., Rutty C. J., Abel G., Gumbrell L. A., Graham M. A., Evans B. D., Wilman D. E., Ashley S. E., Cairnduff F. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). Cancer Res. 1989 Oct 1;49(19):5475–5479. [PubMed] [Google Scholar]
  22. Judson I., Briasoulis E., Raynaud F., Hanwell J., Berry C., Lacey H. Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer. 1997;75(4):608–613. doi: 10.1038/bjc.1997.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kerr D. J., Kaye S. B., Cassidy J., Bradley C., Rankin E. M., Adams L., Setanoians A., Young T., Forrest G., Soukop M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res. 1987 Dec 15;47(24 Pt 1):6776–6781. [PubMed] [Google Scholar]
  24. Kerr D. J., Kaye S. B., Graham J., Cassidy J., Harding M., Setanoians A., McGrath J. C., Vezin W. R., Cunningham D., Forrest G. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res. 1986 Jun;46(6):3142–3146. [PubMed] [Google Scholar]
  25. McKeage M. J., Mistry P., Ward J., Boxall F. E., Loh S., O'Neill C., Ellis P., Kelland L. R., Morgan S. E., Murrer B. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol. 1995;36(6):451–458. doi: 10.1007/BF00685793. [DOI] [PubMed] [Google Scholar]
  26. McKeage M. J., Raynaud F., Ward J., Berry C., O'Dell D., Kelland L. R., Murrer B., Santabárabara P., Harrap K. R., Judson I. R. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol. 1997 Jul;15(7):2691–2700. doi: 10.1200/JCO.1997.15.7.2691. [DOI] [PubMed] [Google Scholar]
  27. Mick R., Ratain M. J. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993 Feb 3;85(3):217–223. doi: 10.1093/jnci/85.3.217. [DOI] [PubMed] [Google Scholar]
  28. Millward M. J., Newell D. R., Mummaneni V., Igwemezie L. N., Balmanno K., Charlton C. J., Gumbrell L., Lind M. J., Chapman F., Proctor M. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer. 1995 Dec;31A(13-14):2409–2411. doi: 10.1016/0959-8049(95)00331-2. [DOI] [PubMed] [Google Scholar]
  29. Newlands E. S., Blackledge G. R., Slack J. A., Rustin G. J., Smith D. B., Stuart N. S., Quarterman C. P., Hoffman R., Stevens M. F., Brampton M. H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992 Feb;65(2):287–291. doi: 10.1038/bjc.1992.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Newlands E. S., Blackledge G., Slack J. A., Goddard C., Brindley C. J., Holden L., Stevens M. F. Phase I clinical trial of mitozolomide. Cancer Treat Rep. 1985 Jul-Aug;69(7-8):801–805. [PubMed] [Google Scholar]
  31. Newlands E. S., Rustin G. J., Brampton M. H. Phase I trial of elactocin. Br J Cancer. 1996 Aug;74(4):648–649. doi: 10.1038/bjc.1996.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. O'Quigley J., Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med. 1991 Nov;10(11):1647–1664. doi: 10.1002/sim.4780101104. [DOI] [PubMed] [Google Scholar]
  33. Penta J. S., Rosner G. L., Trump D. L. Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol. 1992;31(3):247–250. doi: 10.1007/BF00685555. [DOI] [PubMed] [Google Scholar]
  34. Penta J. S., Rozencweig M., Guarino A. M., Muggia F. M. Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol. 1979;3(2):97–101. doi: 10.1007/BF00254979. [DOI] [PubMed] [Google Scholar]
  35. Philip P. A., Rea D., Thavasu P., Carmichael J., Stuart N. S., Rockett H., Talbot D. C., Ganesan T., Pettit G. R., Balkwill F. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst. 1993 Nov 17;85(22):1812–1818. doi: 10.1093/jnci/85.22.1812. [DOI] [PubMed] [Google Scholar]
  36. Prendiville J., Crowther D., Thatcher N., Woll P. J., Fox B. W., McGown A., Testa N., Stern P., McDermott R., Potter M. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer. 1993 Aug;68(2):418–424. doi: 10.1038/bjc.1993.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rafi I., Boddy A. V., Calvete J. A., Taylor G. A., Newell D. R., Bailey N. P., Lind M. J., Green M., Hines J., Johnstone A. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol. 1998 Mar;16(3):1131–1141. doi: 10.1200/JCO.1998.16.3.1131. [DOI] [PubMed] [Google Scholar]
  38. Rafi I., Taylor G. A., Calvete J. A., Boddy A. V., Balmanno K., Bailey N., Lind M., Calvert A. H., Webber S., Jackson R. C. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clin Cancer Res. 1995 Nov;1(11):1275–1284. [PubMed] [Google Scholar]
  39. Ratain M. J., Mick R., Schilsky R. L., Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20;85(20):1637–1643. doi: 10.1093/jnci/85.20.1637. [DOI] [PubMed] [Google Scholar]
  40. Rozencweig M., Von Hoff D. D., Staquet M. J., Schein P. S., Penta J. S., Goldin A., Muggia F. M., Freireich E. J., DeVita V. T., Jr Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials. 1981;4(1):21–28. [PubMed] [Google Scholar]
  41. Simon R., Freidlin B., Rubinstein L., Arbuck S. G., Collins J., Christian M. C. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997 Aug 6;89(15):1138–1147. doi: 10.1093/jnci/89.15.1138. [DOI] [PubMed] [Google Scholar]
  42. Smith D. B., Ewen C., Mackintosh J., Fox B. W., Thatcher N., Scarffe J. H., Vezin R., Crowther D. A phase I and pharmacokinetic study of amphethinile. Br J Cancer. 1988 Jun;57(6):623–627. doi: 10.1038/bjc.1988.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Smith D. B., Fox B. W., Thatcher N., Steward W. P., Scarffe J. H., Wagstaff J., Vezin R., Crowther D. Phase I clinical trial of methylene dimethane sulfonate. Cancer Treat Rep. 1987 Sep;71(9):817–820. [PubMed] [Google Scholar]
  44. Stuart N. S., Crawford S. M., Blackledge G. R., Newlands E. S., Slack J., Hoffman R., Stevens M. F. A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol. 1989;23(5):308–310. doi: 10.1007/BF00292409. [DOI] [PubMed] [Google Scholar]
  45. Vasey P. A., Kaye S. B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A. H., Murray L. S., Hilditch T. E., Murray T. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999 Jan;5(1):83–94. [PubMed] [Google Scholar]
  46. Veale D., Carmichael J., Cantwell B. M., Elford H. L., Blackie R., Kerr D. J., Kaye S. B., Harris A. L. A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer. 1988 Jul;58(1):70–72. doi: 10.1038/bjc.1988.164. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES